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SALL1 functions as a tumor suppressor in
breast cancer by regulating cancer cell
senescence and metastasis through the
NuRD complex
Chunling Ma1,2†, Fang Wang1,3†, Bing Han1,4†, Xiaoli Zhong1, Fusheng Si1, Jian Ye1, Eddy C. Hsueh5,
Lynn Robbins6,7, Susan M. Kiefer1, Yanping Zhang5, Pamela Hunborg5, Mark A. Varvares8,9,
Michael Rauchman6,7* and Guangyong Peng1*

Abstract
Background: SALL1 is a multi-zinc finger transcription factor that regulates organogenesis and stem cell
development, but the role of SALL1 in tumor biology and tumorigenesis remains largely unknown.
Methods: We analyzed SALL1 expression levels in human and murine breast cancer cells as well as cancer tissues
from different types of breast cancer patients. Using both in vitro co-culture system and in vivo breast tumor
models, we investigated how SALL1 expression in breast cancer cells affects tumor cell growth and proliferation,
metastasis, and cell fate. Using the gain-of function and loss-of-function strategies, we dissected the molecular
mechanism responsible for SALL1 tumor suppressor functions.
Results: We demonstrated that SALL1 functions as a tumor suppressor in breast cancer, which is significantly
down-regulated in the basal like breast cancer and in estrogen receptor (ER), progesterone receptor (PR) and
epidermal growth factor receptor 2 (HER2) triple negative breast cancer patients. SALL1 expression in human and
murine breast cancer cells inhibited cancer cell growth and proliferation, metastasis, and promoted cell cycle arrest.
Knockdown of SALL1 in breast cancer cells promoted cancer cell growth, proliferation, and colony formation. Our
studies revealed that tumor suppression was mediated by recruitment of the Nucleosome Remodeling and
Deacetylase (NuRD) complex by SALL1, which promoted cancer cell senescence. We further demonstrated that the
mechanism of inhibition of breast cancer cell growth and invasion by SALL1-NuRD depends on the p38 MAPK,
ERK1/2, and mTOR signaling pathways.
Conclusion: Our studies indicate that the developmental control gene SALL1 plays a critical role in tumor
suppression by recruiting the NuRD complex and thereby inducing cell senescence in breast cancer cells.
Keywords: SALL1, Tumor suppressor gene, Senescence, NuRD complex, Tumorigenesis, Metastasis, Breast cancer
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Background
The human SALL gene family, SALL1-SALL4, was identified as homologues to the Drosophila homeotic gene
spalt [1–3]. Originally, the SALL family are zinc finger
transcription factors that were shown to function as critical regulators in the development of multiple mammalian
organs, including kidney, heart, and the hematopoietic
system [4–6]. Mutations in the human SALL1 and SALL4
genes result in Townes-Brocks (TBS) and Okihiro syndrome (OS), respectively [1, 5, 7]. The SALL gene family is
also important for the control of stem cell pluripotency,
differentiation and self-renewal properties involving transcriptional and epigenetic actions [6, 8–10].
Besides the regulation of organ and stem cell development, the role of SALL genes in tumor biology and
tumorigenesis has been recently investigated. SALL2 has
been reported as a potential tumor suppressor in ovarian
cancer and Wilms tumor [11–13]. SALL4 was shown to
regulate survival and apoptosis in human leukemic cells
[14, 15]. Furthermore, SALL4 was recently identified as
a novel marker for hepatoblastoma, non-small cell lung
carcinoma, and gastric cancinoma [16, 17]. Mutations in
SALL3 have been discovered in a significant proportion
of Burkitt’s lymphoma cases [18]. It has been shown that
the SALL1 promoter was methylated in breast and other
epithelial cancers [19], but little is known about the role
of SALL1 in the pathogenesis of human cancers. A recent
report identified SALL1 as a tumor suppressor in human
breast cancer, using an in vivo RNAi screen strategy [20].
However, the molecular mechanism and causative role of
SALL1 in the regulation of breast cancer development
and tumorigenesis are not well understood.
The role of SALL1 in the regulation of organogenesis
of the kidney has been extensively studied by our group
and others. We have demonstrated that SALL1 recruits
and binds to the nucleosome remodeling and deacetylase
(NuRD) chromatin remodeling complex and their combined action is required to maintain renal progenitor
cells [4, 6, 21–23]. We identified a highly conserved 12amino acid motif in the SALL1 that is sufficient for the
recruitment of NuRD [22]. We showed that protein kinase C phosphorylates serine 2 of SALL1 repression motif
to regulate SALL1-mediated NuRD recruitment and its
associated functions [21]. Importantly, increasing evidence suggests that the NuRD protein complex plays an
essential role in cancer development and metastasis [24].
Specifically, several subunits of NuRD, such as MTA1,
MTA3, and Mi-2 can directly control the cancer invasive
growth, epithelial-to-mesenchymal transition, and metastasis in breast cancer [24–26]. Given the recent study
identifying that SALL1 could be a tumor suppressor in
human breast cancer [20], it is important to determine
how SALL1 regulates breast cancer cell biology and
functions. In addition, whether SALL1 recruits the
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NuRD complex to perform its tumor suppressor function in breast cancer is unclear. Improved understanding
of these molecular processes mediated by SALL1 for the
regulation of tumor biology and tumorigenesis will open
new avenues to develop novel therapeutic strategies in
human breast cancer and possibly other tumors.
To better understand the role of SALL1 in the pathogenesis of breast cancer, we investigated the mechanism
of SALL1 tumor suppressor activity in breast cancer
models. Using both gain-of function and loss-of-function
strategies, we showed that SALL1 expression in breast
cancer cells inhibited tumor cell growth and proliferation,
promoted cell cycle arrest, and induced cell senescence.
We further revealed that SALL1 tumor suppressor activity
depended on its ability to recruit NuRD and that this molecular process was controlled by MAPK p38 and ERK1/2,
and mTOR signaling pathways in cancer cells. In addition,
our complementary in vivo studies demonstrated that
SALL1 expression and NuRD recruitment in breast tumor
cells inhibited tumorigenesis and metastasis in breast cancer models in vivo. Collectively, these studies suggest that
SALL1 functions as a tumor suppressor in breast cancer
and directly controls cancer cell fate and metastasis.

Results
SALL1 expression is down-regulated in human breast cancer cell lines and tissues

We investigated whether SALL1 could function as a
tumor suppressor and dissected the molecular mechanism
by which it regulates human breast cancer. We first determined SALL1 gene expression levels in breast cancer cell
lines using Real-time PCR analyses. In parallel, SALL1 expression in cancer cell lines from other types of cancers
(melanoma, prostate cancer, colon cancer and lymphoma),
as well as in normal breast primary cell lines, fibroblasts
and 293 T cells were also determined. We observed markedly elevated SALL1 gene expression in all melanoma cell
lines and moderate gene expression in normal fibroblasts
and 293 T cells (Fig. 1a). In contrast, SALL1 gene expression levels in all the tumor cell lines from breast cancer,
prostate cancer, colon cancer and lymphoma were significantly down-regulated. In addition, SALL1 expression in
normal primary breast cells and cell lines (BN6, BN16,
MCF10A and MCF12A) were also relatively low compared with normal fibroblasts and 293 T cells. These results were further confirmed in human breast and
melanoma tumor tissues, showing down-regulation of
SALL1 gene in breast cancer tissues (Fig. 1b). Clinically
breast cancers can be classified into several distinct subtypes based on the histopathology and molecular characteristics which are associated with the therapeutic options
and prognostic outcomes. To further investigate the association of SALL1 gene expression with breast cancer subtypes, we utilized The Cancer Genome Atlas (TCGA)
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Fig. 1 SALL1 expression is down-regulated in human breast cancer. a and b Gene expression levels of SALL1 in different cancer cell lines (in a)
and in tumor tissues (in b) using Real-time PCR analyses. Tumor cell lines include breast cancer (human MDA-MB-231, MCF7, BC80, 31, 30, 29, 16,
12, and 10), melanoma (human Mel1938, Mel1586, Mel1860, Mel1363, Mel1526 and Mel1628), prostate cancer (PC3 and DU145), colon cancer
(SW480), and lymphoma (L428 and L504). Normal breast cell lines (BN6, BN16, MCF10A and MCF12A), Fibroblasts (F163, F160, F158 and F112) and
293 T cells were included as controls. mRNA levels in each cell line and tissue were normalized to the relative quantity of GAPDH expression and
then adjusted to SALL1 levels in 293 T cells (set as 1). Results shown in the histogram are mean ± SD from three independent experiments. c and d Association analyses of SALL1 expression with specific breast cancer subtypes. The data sets were accessed from the TCGA breast cancer Argilent microarray expression database downloaded from the cBioPortal (http://www.cbioportal.org/). The box plot indicated the log 2 transformed mRNA median
expression level of SALL1 in the tissues. N indicated the number of sample size of each tissue type. Mann-Whitney analysis was used to compare the
SALL1 expression across the different breast cancer subtypes and normal tissues, and **p < 0.01 within the comparison groups. e SALL1 expression in
tumor cells in breast cancer tissues was determined using the immunohistochemical staining. f and g SALL1 expression levels in breast cancer tissues
with different ER and HER2 status. SALL1+ cell population in ER+ patients was significantly higher than that in ER− patients. Furthermore, SALL1+ cell
numbers in HER2+ patients were much higher than that in HER2− patients. Tissue immunohistochemical staining and cell number counting were identical as in (e). Significance was determined by unpaired T test

normalized log2 transformed breast cancer agilent microarray expression data sets downloaded from the cBioPortal (http://www.cbioportal.org/) for our studies [27].
Breast cancers have been designated as luminal A, luminal
B, epidermal growth factor receptor 2 (HER2) enriched,

basal like and normal like, five important categories based
on gene expression profiles [28]. We found a substantial
decrease of SALL1 expression in the basal like breast cancer compared with that in normal breast tissue (p < 0.001)
(Fig. 1c), which is consistent with the previous report [20].
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Furthermore, we also compared SALL1 expression in
breast cancer patients with different hormone receptors,
estrogen receptor (ER) and Progesterone receptor (PR), or
HER2 expression statuses (Fig. 1d). The analysis revealed
that there was significantly lower expression of SALL1 in
the ER− breast cancer than that in the ER+ cancer tissues
and normal breast tissues (p = 0.006 and p = 0.008, respectively). Similarly the SALL1 expression was lower in
PR− breast cancer than that in PR+ breast cancer or the
normal breast tissues (p < 0.001 and p = 0.0059, respectively). Importantly, we also found a significant lower expression level of SALL1 in triple negative breast cancer
tumors (ER−, PR−, and Her2−) compared with that in normal breast tissues (p = 0.0021). To further investigate the
SALL1 expression in human breast cancer, we determined
the SALL1+ cell numbers in cancer tissues from breast
and melanoma cancer patients, using immunohistochemical staining analyses. Consistent with the gene expression
results (Fig. 1b), we found that melanoma tumor tissues
contained larger numbers of SALL1+ cells (mean 232/
field), while in breast cancer tissues, the SALL1+ cells were
low (mean 50/field) (Fig. 1e and Additional file 1: Figure
S1A). Notably, SALL1+ cell numbers in ER− patients were
significant lower than those in ER+ patients (Fig. 1f). In
addition, SALL1+ cell population in HER2+ patients was
much higher than that in HER2− patients (Fig. 1g). To further identify mechanism(s) responsible for the downregulation of SALL1 gene in breast cancer, we explored
the mutations and promoter methylation status of the
SALL1 gene via The Catalogue of Somatic Mutations in
Cancer (COSMIC) genome browser [27]. However, we did
not identify any mutations that could account for SALL1
down-regulation in breast cancer (Additional file 1: Figure
S1B). Previous study has shown that the SALL1 promoter
was methylated in breast and other epithelial cancers [19].
We selected two probes that indicate a methylation difference of the SALL1 promoter in COSMIC between the primary tumor in breast cancer and solid normal tissues. We
observed that the genes were highly methylated in these 2
regions of SALL1 promoter in the breast cancer tissues,
which might be partially responsible for the downregulation of SALL1 in breast cancer (Additional file 1:
Figure S1C). Recent studies have shown that SALL4 is involved in leukemogenesis and a marker for hepatoblastoma and non-small cell lung carcinoma [15–17]. We
therefore determined SALL4 gene expression in breast
cancer cell lines and primary cancer tissues. In contrast to SALL1 gene expression, we found significantly
higher expression of SALL4 in both breast cancer cell
lines and primary cancer tissues, suggesting that
SALL1 and SALL4 may have distinct functional roles
in the regulation of breast cancer (Additional file 1:
Figure S1D and E). Collectively, our results suggest
that SALL1 expression is significantly down-regulated
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in human breast cancer cells and in certain types of
breast cancer tissues (especially in triple negative
breast cancer), which may play a critical role in the
pathogenesis of human breast cancer.
SALL1 over-expression in breast cancer cells inhibits
tumor cell growth and proliferation, and promotes cell
cycle arrest

To test whether SALL1 is a tumor suppressor [20], we determined the effect on cancer cell growth and function by
SALL1. SALL1 was transfected into human and murine
breast cancer cell lines MDA-MB-231 (TNBC), MCF7
and E0771 (basal-like) (all with no or minor expression of
SALL1) for the gain-of-function studies. Prostate cancer
cell line PC-3 (low SALL1 expression) and melanoma cell
line B16F0 (high SALL1 expression), as well as normal
breast cell line MCF12A cells were included as controls.
Tumor cell growth and proliferation were determined by
analyzing cell growth curves and [3H]-thymidine incorporation assays. We found that transfection of SALL1, but
not SALL4 or vector in MCF-7, MDA-MB-231, E0771
and PC-3 tumor cells significantly inhibited cell growth
and proliferation. However, over-expression of SALL1 in
B16F0 melanoma cells, and normal breast cell MCF12A
did not affect cell growth and proliferation (Fig. 2a and b,
and Additional file 1: Figure S2A and B). These results further suggest that SALL1 directly inhibits breast cancer cell
growth, but it may have different functions in the other
types of cancers.
Suppression of tumor cell proliferation and growth mediated by SALL1 expression could be due to the induction
of apoptosis or cytolysis in the tumor cells. We therefore
measured apoptosis and cell death in SALL1-transfeced
breast tumor cells. We found that breast tumor cells
MCF7, MDA-MB-231 and E0771 in medium alone or
transfected with control vector contained some apoptotic
cells (around 10% in MCF-7, 4% in MDA, and 20% in
E0771). However, overexpression of SALL1 in cancer cells
did not induce increased apoptosis or cell death in breast
cancer cell lines (Fig. 2c and Additional file 1: Figure S2C).
In parallel, we studied the cell cycle distribution of the
breast cancer cells transfected with SALL1. SALL1 transfection in MCF-7, MDA and E0771 cells significantly induced cancer cells to arrest in S phase and decrease in
G0/G1 phase (Fig. 2d). Notably, transfection of SALL1 in
melanoma B16F0 cells induced neither cell apoptosis
nor cell cycle arrest. To further identify the potential
mechanism responsible for the SALL1-mediated breast
cancer cell arrest in S phase, we determined the cell
cycle regulation gene expressions in MDA-MB-231
cells using Real-time PCR analysis, including Cyclin A2,
B1, D1 and E1, as well as CDK2, 4 and 6. We observed
that transfection with SALL1 significantly increased the
gene expressions of Cyclin A2, Cyclin B1, Cyclin E1,
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Fig. 2 Over-expression of SALL1 in breast cancer cells inhibits tumor cell growth and proliferation, and promotes cell cycle arrest. a and b
Transfection of SALL1 but not SALL4 significantly inhibited breast cancer cell growth and proliferation. However, over-expression of SALL1 in
B16F0 melanoma cells and normal MCF12A cells (controls) did not affect cell growth and proliferation. Cells transfected with or without plasmids
pcDNA3.1-SALL1, pcDNA3.1-SALL4, and pcDNA3.1, were cultured at a starting number of 2 × 104/well in 24 wells (a), or 1 × 104/well in 96-well
plates (b). Cell growth was evaluated at different time points using by counting cell number (in a), and cell proliferation was determined using
[3H]-thymidine assays (in b). Data are mean ± SD from three independent experiments with similar results. **p < 0.01 compared with the vector
control group. c The suppression of breast cancer cell proliferation and growth mediated by SALL1 expression is not due to cell apoptosis. Transfected breast cancer and melanoma cells were cultured for additional 72 h. Apoptosis in transfected tumor cells was analyzed after staining with
PE-labeled Annexin V and 7-AAD. Data shown are representative of three independent experiments with similar results. d SALL1 transfection in
MCF-7, MDA-MB-231 and E0771 cells, but not in melanoma B16F0 cells significantly promoted cancer cell cycle arrest in S phase and decrease in
G0/G1 phase. Cell treatment was the same as in (c). Cell cycle distribution in tumor cells was analyzed after incubation with 10 μg/ml propidium
iodide and 100 μg/ml RNase A. B16F0 melanoma cells served as a control. Data are representative of three independent experiments with
similar results

CDK2 and CDK4 in breast cancer MDA cells, which
are important for checkpoint regulation in G1-S transition and S phases (Additional file 1: Figure S3). These
data suggest that over-expression of SALL1 in breast cancer strongly suppresses tumor growth and proliferation, as
well as induces cell cycle arrest, which is mechanistically
independent of apoptosis or cytolysis in tumor cells.
Knockdown of SALL1 in breast cancer cells promotes
tumor cell growth, proliferation, and colony formation

To further confirm the functional role of SALL1 in regulating breast cancer cell growth, we also utilized a loss-

of-function strategy to knockdown SALL1 gene expression with lentivirus-based shRNA in breast cancer cell
lines and then determined its effect on tumor growth
and proliferation. As expected, silencing of SALL1 expression in MCF-7, MDA-MB-231 and E0771 breast cancer
cells dramatically promoted tumor growth and increased
cell proliferation compared with lentivirus carrying control shRNA infected breast cancer cells (Fig. 3a and b).
Furthermore, the numbers and sizes of tumor cell
colonies were also significantly increased in three
breast tumor cell lines after knockdown of SALL1 in
a colony formation assay (Fig. 3c and d). In contrast,

Ma et al. Molecular Cancer (2018) 17:78
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Fig. 3 Knockdown of SALL1 in breast cancer cells promotes tumor cell growth, proliferation, and colony formation. a and b Knockdown of SALL1
significantly promoted breast cancer cell growth and proliferation. However, over-expression of SALL1 dramatically inhibited breast cancer cell
growth and proliferation. In addition, knockdown or over-expression of SALL1 in normal breast cells MCF12A (control) did not affect cell growth
and proliferation. Tumor or normal cells were infected with lentivirus carrying shRNA specific for SALL1 or scramble shRNA control, or transfected
with or without plasmids pcDNA3.1-SALL1, and then were cultured at a starting number of 2 × 104/well in 24 wells (a), or 1 × 104/well in 96-well
plates (b). Cell growth was evaluated at different time points using by counting cell number (in a), and cell proliferation was determined using
[3H]-thymidine assays (in b). Data are mean ± SD from three independent experiments with similar results. **p < 0.01 compared with the control
shRNA and medium only groups. c and d Knockdown of SALL1 expression in breast cancer cells dramatically increased numbers and sizes of
tumor colonies, while over-expression of SALL1 significantly inhibited breast cancer cell colony formation ability. Five thousand per well of tumor
cells with the indicated treatments were cultured in soft agar in 6-well plate for 3 weeks and examined for their anchorage-dependent colony formation ability. Results shown in the histogram (in d) are mean ± SD from three independent experiments. **p < 0.01 compared with the control
shRNA and medium only groups

over-expression of SALL1 in breast cancer cells dramatically inhibited tumor cell grown and proliferation,
as well as decreased colony numbers, which were
consistent with the results shown in Fig. 2. In
addition, we did not observe any effects of SALL1

overexpression or down-regulation on cell growth and
proliferation in normal breast MCF12A cells. These
results further suggest that SALL1 expression in
breast cancer cells directly controlled cell growth and
function.

Ma et al. Molecular Cancer (2018) 17:78

SALL1 over-expression in breast cancer cells induces
tumor cell senescence

Senescent human cells have permanent growth arrest,
which could occur due to telomere shortening or a DNA
damage response [29, 30]. We therefore reasoned that
induction of senescence might be the mechanism involved in the suppressed cell growth and proliferation
mediated by SALL1 overexpression in breast cancer
cells. In addition to cell cycle arrest and morphologic
characteristics, SA-β-Gal is the first biomarker used to
identify senescent human cells [31, 32]. We observed
that transfection of SALL1 in MCF-7, MDA, and E0771
tumor cells significantly increased the number of SA-βGal+ cells, indicating the induction of tumor cell senescence (Fig. 4a and b, and Additional file 1: Figure S4A).
In contrast, transfection with SALL4 or control vector in
these tumor cells did not induce increased SA-β-Gal expression. In addition, we did not observe increased senescent cell populations in melanoma B16F0 cells after
over-expression of SALL1.
The induction of DNA damage is the key molecular
process in senescent cells, which could be induced by
telomere erosion and/or other forms of stress. The nuclear kinase ataxia-telangiectasia mutated protein (ATM)
is the chief inducer of the DNA-damage response. We
thus determined whether induction of ATM-associated
DNA damage is the main trigger for SALL1-induced
senescence in breast tumor cells [33, 34]. Overexpression of SALL1 significantly induced active, phosphorylated ATM in MCF-7, MDA and E0771 cancer
cells (Fig. 4c and Additional file 1: Figure S4B). In
addition, we further investigated the other key DNA
damage response proteins involved in the induction of
senescence due to the DNA damage response. These
proteins include ATM substrates H2AX and 53BP1, as
well as the downstream target checkpoint kinase 2
(CHK2) [30, 34]. We observed that transfection of
SALL1, but not SALL4 or control vector also significantly induced phosphorylation of H2AX, 53BP1 and
CHK2 in MCF-7, MDA and E0771 cells (Data not
shown). To confirm the involvement of ATM-associated
DNA damage response in SALL1-mediated breast cancer
cell senescence, we next determined whether we can prevent the SALL1-mediated senescence in breast cancer
cells through the functional blockade of ATM-induced
DNA damage using loss-of-function approaches with the
specific pharmacological ATM inhibitor KU55933 and
shRNA against ATM. As shown in Fig. 4d, treatment of
MCF-7, MDA and E0771 breast cancer cells with
KU55933 dramatically suppressed the phosphorylation of
ATM in SALL1-transfected tumor cells and prevented induction of senescence in tumor cells. In addition, knockdown of ATM expression with shRNA significantly
decreased the senescent cell populations in SALL1-
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transfected breast tumor cells, further confirming the involvement of the ATM-associated DNA damage response
in SALL1-induced tumor cell senescence (Fig. 4e). These
data provide the first evidence that suppression of breast
cancer growth and proliferation mediated by SALL1 expression is due to the induction of tumor cell senescence.
SALL1 recruits NuRD in breast cancer performing a tumor
suppressor function

Our previous studies have shown that endogenous SALL1
binds to the NuRD complex to regulate gene transcription
and specific developmental processes [4, 6, 21–23]. We
further identified a highly conserved 12-amino acid motif
in the SALL1 protein that is sufficient for the recruitment
of NuRD [22]. Importantly, increasing evidence suggests
that the NuRD complex plays an essential role in regulating oncogenesis and metastasis programs of breast cancer
[24–26]. We therefore hypothesized that SALL1-mediated
suppression of breast cancer growth and proliferation, and
induction of tumor cell senescence may also act through
the recruitment of the NuRD complex. To test this hypothesis, we first transfected a mutated SALL1 (mSALL1)
encoding a protein in which the conserved 12-amino acid
peptide motif that specifically binds to NuRD was deleted,
into breast cancer cells and determined the capacity for
senescence induction (Additional file 1: Figure S5). Consistent with the above results, transfection of full-length
SALL1 into MCF-7 and E0771 breast cancer cells significantly induced tumor cell senescence (around 40%)
and promoted cell cycle arrest in S phase in 3 days
(Fig. 5a and b). However, transfection of the mutated
SALL1 in the breast cancer cells did not have any effects on cell senescence and cell cycle, similar to that of
control vector, suggesting that breast cancer cell senescence mediated by SALL1 depends on NuRD recruitment.
In our efforts to identify the relationship and direct interactions between SALL1 and NuRD, we have demonstrated that protein kinase C phosphorylates serine 2 of
the SALL1 repression motif and regulates the association
with NuRD [21]. Furthermore, we showed that substitution of the serine with a glutamic acid (SALL1-S2E,
phosphomimetic) significantly abolished the effect on
NuRD recruitment and repression activity; whereas
mutating the serine to an alanine (SALL1-S2A) modestly
increased the transcriptional repression [21, 22]
(Additional file 1: Figure S5). We next utilized SALL1
constructs with these two separation-of-function mutations to test its effects on senescence induction in breast
cancer cells. As we expected, transfection of SALL1-S2E
into MCF-7 and E0771 breast cancer cells lost the ability
to induce tumor cell senescence. In contrast, transfection of SALL1-S2A into tumor cells significantly augmented senescence induction in both cell lines
compared with that of wild type SALL1-transfected
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Fig. 4 SALL1 over-expression in breast cancer cells induces tumor cell senescence and ATM-associated DNA damage response. a and b Transfection of SALL1, but not SALL4 in MCF-7, MDA-MB-231 and E0771 breast cancer cells significantly induced the increased SA-β-Gal+ cells. In contrast,
over-expression of SALL1 in B16F0 melanoma cells did not increase senescent cell populations. Transfected tumor cells were cultured for an additional 5 days. Senescent cells were analyzed using the SA-β-Gal activity assay and the SA-β-Gal+ tumor cells were identified with dark blue granules as indicated by the arrows (in a). Data shown in (b) are mean ± SD from three independent experiments with similar results. **p < 0.01
compared with the vector control group. c SALL1 expression in breast cancer cells induced phosphorylated activation of ATM in the transfected
cells. Transfected tumor cells were determined for the p-ATM expression after culture for 3 additional days using FACS analyses. d Pretreatment
of breast cancer cells with an ATM specific inhibitor KU55933 significantly prevented the induction of tumor cell senescence induced by SALL1
expression. Tumor cells were pretreated with or without KU55933 (20 μM) for 1 day, and then transfected with SALL1. SA-β-Gal expression in the
transfected tumor cells was determined with SA-β-Gal staining after culture for 3 additional days. Data shown are mean ± SD from three
independent experiments, and paired t-test was performed. **p < 0.01, compared with the medium only control group. e Knockdown of
ATM gene by shRNAs in MCF-7, MDA-MB-231 and E0771 cells dramatically blocked SALL1-induced tumor cell senescence. Breast cancer
cells were transfected with lenti-shRNAs specific for ATM or control shRNAs. Transduced cancer cells were then transfected with SALL1
and cultured for 5 days. The SA-β-Gal+ cancer cells were determined. **p < 0.01, compared with the group transduced with the control
shRNA. Data shown are representative of three independent experiments with similar results

tumor cells (Fig. 5c and d). To confirm the physical
interaction of SALL1 with the NuRD complex in cancer
cells, we transfected MCF-7 breast cancer cells with
GST fusions of wild type SALL1, or SALL1-S2A and
SALL1-S2E. GST-SALL1 fusion proteins were isolated
on glutathione-Sepharose beads. Western-blot assays
were then performed to determine the expression of
components of the NuRD complex, including MTA2,
RbAp46/48, HDAC1 and MBD3, after SALL1 and GST

pulldown [21, 22]. Transfection of the three fusion constructs equivalently expressed SALL1 protein (Fig. 5e).
Expression of wild type SALL1 and SALL1-S2A in MCF7 tumor cells recruited the endogenous NuRD complex
components. However, GST-SALL-S2E did not pulldown
NuRD components even though it is expressed at a level
comparable to wild type SALL1. Collectively, these
results clearly indicate that SALL1 recruits NuRD in
breast cancer cells resulting in suppression of tumor
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Fig. 5 Involvement of NuRD complex in the regulation of breast cancer cell senescence and suppression mediated by SALL1. a and b
Transfection of mutated SALL1 (mSALL1, deleted the NuRD binding peptide motif of conserved 12-amino) in MCF-7 and E0771 cancer cells did
not induce SA-β-Gal+ cell populations (in a) and promote cancer cell cycle arrest in S phase (in b). In contrast, transfection of full-length SALL1
into MCF-7 and E0771 breast cancer cells significantly induced tumor cell senescence (around 40%) and promoted cell cycle arrest in S phase.
Breast cancer cells were transfected with the indicated constructs and cultured for additional 72 h. Senescent cells were analyzed using the SA-βGal activity assay and the cell cycle distribution in tumor cells was analyzed after incubation with propidium iodide. Data shown in (a) are mean
± SD from three independent experiments with similar results. **p < 0.01 compared with the mSALL1 and vector control groups. c and d Transfection of SALL1-S2E into MCF-7 and E0771 breast cancer cells lost the ability to induce tumor cell senescence. However, transfection of SALL1S2A into breast cancer cells significantly augmented senescence induction in both cell lines compared with that of in wild type SALL1-transfected
tumor cells. Cell transfection procedure and SA-β-Gal+ cell determination were identical to (a). SALL1-S2E: substitution of the serine with a glutamic acid in SALL1. SALL1-S2A: mutating the serine to an alanine in SALL1. SA-β-Gal+ tumor cells were identified with dark blue granules as indicated by the arrows (in c). Data shown in (d) are mean ± SD from three independent experiments with similar results. **p < 0.01, compared with
the vector control group. #p < 0.01, compared with the wild type SALL1 group. e Transfection of wild type SALL1 and SALL1-S2A into MCF-7
tumor cells recruited NuRD complex components determined with GST pulldown analyses. In contrast, transfection of SALL1-S2E markedly disrupted recruitment of NuRD components. MCF-7 cells were transfected with or without plasmids pEBG-SALL1, pEBG-SALL1-S2A, and pEBG-SALL1S2E, and cultured for 3 days. Total protein lysates precipitated with Protein G-Sepharose beads. Pulldowns were analyzed by western blotting with
antibodies against SALL1, HDAC1, MTA2, MBD3 and RbAp46/48

growth and proliferation, and induction of tumor cell
senescence.
SALL1 induces selective modulation of MAPK p38 and
ERK1/2, and mTOR signaling pathways in breast cancer
cells

SALL proteins heterodimerize and in some contexts can
cross-regulate their respective expression. We thus determined whether SALL1 could alter the expression of

other members in the SALL family mediating breast
cancer growth suppression [10]. Our results showed that
transfection of SALL1 in both MCF-7 and E0771 cells
did not change the gene expression levels of SALL2,
SALL3 and SALL4 at different time points using Realtime PCR analyses (Additional file 1: Figure S6).
MAPK signaling pathways play a major role in regulating cell cycle re-entry and oncogenic ras-induced senescence [35]. It has been reported that ERK1/2 and p38
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activation can induce p21-dependent G1 cell cycle arrest
[36]. Our recent studies further demonstrated that
MAPK ERK1/2 and p38 signaling controls the molecular
process of human CD4+CD25hiFoxP3+ Treg-induced
responder T cell senescence [32, 34]. We therefore explored whether SALL1-induced breast cancer cell cycle
S phase arrest and conversion of cancer cells into senescent cells involved MAPK signaling modulation. We first
determined the activation and phosphorylation of
MAPKs, including ERK1/2, p38 and JNK in breast cancer cells transfected with SALL1 using western blot analyses. We found that transfection of SALL1 but not
mutated SALL1 selectively activated ERK1/2 and p38,
but not JNK, resulting in significantly enhanced phosphorylation of ERK1/2 and p38 in both MCF-7 and
E0771 breast cancer cells (Fig. 6a). To further determine
the role of ERK1/2 and p38 signaling in controlling the
molecular process of SALL1-induced senescence in
breast cancer cells, we utilized loss-of-function strategies
with specific pharmacological inhibitors and lentivirusbased shRNAs to block ERK1/2 and p38 activities in
breast cancer cells, as we previously described [32]. The
optimal concentrations (10 μM) of different inhibitors
used for our experiments, including SB203580 (p38 inhibitor) and U0126 (ERK1/2 inhibitor), were selected
based on their toxic effects on tumor cell viability and
proliferation. As shown in Fig. 6b, we observed that inhibitors U0126 and SB203580 significantly reduced
SALL1-induced senescent cell populations in both MCF7 and E0771 breast tumor cells. We then used shRNAs
to specifically knock down p38 and ERK1/2 genes in
MCF-7 and E0771 cells, and measured the effects on
SALL1-induced tumor cell senescence. Consistent with
the results obtained in inhibitor experiments described
above, knockdown of p38 and ERK1/2 in MCF-7 and
E0771 cells significantly decreased the senescence induction in SALL1-transfected tumor cells (Fig. 6c). These
results suggest that SALL1 expression in breast cancer
cells induces selective modulation of specific MAPK p38
and ERK1/2 signaling pathways in tumor cells that control the molecular process of SALL1-induced tumor cell
senescence and growth suppression. Moreover, this
process depends on an intact NuRD-recruitment motif
in SALL1.
In addition to MAPK signaling, mTOR kinase signaling activation is important for tumor cell proliferation
and senescence induction [37–41]. We next investigated
whether mTOR signaling is also involved in the SALL1induced breast cancer growth inhibition and senescence
induction. We determined the activation of mTOR and
its downstream substrates p70S6K and 4E-BP1, in breast
tumor cells after transfection with SALL1 [42]. Transfection of SALL1 but not mutated SALL1 in both MCF-7
and E0771 breast tumor cells significantly induced the
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phosphorylation of mTOR, p70S6K, and 4E-BP1, further
confirming the activation of mTOR signaling in tumor
cells after SALL1 expression (Fig. 6d). Using loss-offunction strategies, we demonstrated that the mTOR inhibitor rapamycin and shRNA to specifically knock
down mTOR gene expression in breast cancer cells dramatically prevented induction of senescence in tumor
cells mediated by SALL1 expression (Fig. 6e and f ).
These results suggest that the mTOR signaling pathway
is also critical in regulating breast cancer cell senescence
mediated by SALL1 expression. Furthermore, our studies
indicate that SALL1 expression in breast cancer selectively utilizes both MAPK and mTOR signaling pathways
controlling tumor cell fate and functions.
SALL1 expression in breast cancer cells inhibits
tumorigenesis and metastasis in vivo

These in vitro studies provided us with important information regarding the mechanism and molecular signaling of SALL1 in suppressing breast cancer tumor cell
growth and metastasis. We next performed complementary in vivo studies, using murine breast cancer E0771
cells in humanized NOD-scid IL2Rγnull (NSG) mouse
models, and explored whether SALL1 functions as a
tumor suppressor for the tumorigenesis and metastasis
of breast cancer in vivo. The E0771 cell line is a basallike and derived from medullary breast adenocarcinoma
cells, representing a good model for spontaneously developed breast cancer [43, 44]. We also included murine
B16F0 melanoma cells as a tumor control for this study.
We first performed xenograft models to investigate
whether over-expression of SALL1 in breast cancer cells
can affect tumor growth and development. Mouse
E0771 and B16F0 tumor cells infected with Lentivirus
carrying SALL1, mSALL1 or vector, were subcutaneously injected into NSG mice. Tumor growth was evaluated. At the end of the experiments, tumors were
isolated from the sacrificed mice and weighed. As shown
in Fig. 7a, we observed that E0771 tumor cells alone or
transfected with mutated SALL1 gene or vector control,
grew progressively in NSG mice. However, overexpression of wild type SALL1 in E0771 cells dramatically inhibited breast tumor progression and growth. Furthermore, tumor sizes collected from the E0771-SALL1
group on day 21 post inoculation were significantly
smaller than those in the control groups of E0771 tumor
alone, E0771 cells transfected with mSALL1 or vector
(Fig. 7b). In addition, the average tumor weights obtained from the E0771-SALL1 group were much lower
than those of the three control groups (Fig. 7c). Notably,
tumor growth, tumor sizes and weights were very similar
among the three control groups of E0771 tumor alone,
E0771 cells transfected with mSALL1 or vector. In contrast to the E0771 breast tumor model, there were no
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Fig. 6 MAPK p38 and ERK1/2, and mTOR signaling pathways control the molecular process of SALL1-induced breast cancer cell senescence. a
Transfection of wild type SALL1 but not mutated SALL1 in MCF-7 and E0771 cells induced phosphorylation of ERK and p38 in senescent tumor
cells. Transfected breast cancer cells were cultured for different time points and cell lysates were prepared for western blot analyses. Results from
western blot analyses of phosphorylated activation of ERK and p38 were shown in the upper panel. Phosphorylated ERK and p38 protein levels
shown in the lower histogram were analyzed quantitatively and compared against the GAPDH expression level with a densitometer. Results
shown in the histogram were means±SD from 3 independent experiments. *p<0.05 and **p<0.01 compared with the mutated SALL1 transfected
group. b Inhibition of ERK1/2 or p38 signaling pathways by specific pharmacological inhibitors significantly prevented breast cancer cell senescence
induced by SALL1, resulting in decreased SA-β-Gal expression. SALL1-transfected MCF-7 and E0771 cancer cells were cultured in the presence
or absence of inhibitors U0126 or SB203580 (10μM) for 5 days. The treated tumor cells were analyzed for SA-β-Gal expression. Data shown are
mean ± SD from three independent experiments with similar results. **p < 0.01, compared with the SALL1-transfected group but not treated
with inhibitor. c Knockdown of ERK1/2 and p38 genes by shRNAs in MCF-7 and E0771 cells dramatically blocked SALL1-induced tumor cell
senescence. Breast cancer cells were infected with lenti-shRNAs specific for ERK1/2 or p38 molecules. Transduced (GFP+) cancer cells were
purified by FACS sorting and then transfected with SALL1 and cultured for 5 days. The SA-β-Gal+ cancer cells were determined. **p < 0.01,
compared with the group transduced with the control shRNA. Data shown are representative of three independent experiments with similar
results. d Phosphorylation and subsequent activation of mTOR signaling in breast cancer cells transfected with SALL1 but not mSALL1. Transfected MCF-7 and E0771 cells cultured for different times, and then were collected for western blot analyses of total and phosphorylated
mTOR, p70S6K, and 4E-BP1 protein levels. e Rapamycin markedly inhibited the SALL1-mediated breast cancer cell senescence. SALL1transfected MCF-7 and E0771 cancer cells were cultured in the presence or absence of mTOR inhibitor rapamycin (5 μM) for 5 days. The
treated tumor cells were stained for SA-β-Gal expression. Data shown are mean ± SD from three independent experiments with similar
results. **p < 0.01, compared with the SALL1-transfected group but not treated with inhibitor. f Knockdown of mTOR by shRNA in MCF-7
and E0771 cells significantly blocked SALL1-induced tumor cell senescence. Transfection procedure was identical to (c) and SA-β-Gal+
cancer cells were determined. **p < 0.01, compared with the group transduced with the control shRNA. Data shown are representative
of three independent experiments with similar results
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differences of tumor growth, progression and sizes
among the experimental groups of B16F0 cells transfected with SALL1, mSALL1 or vector, in the B16F0
melanoma model (Fig. 7a-c). These results were consistent with our in vitro studies showing that SALL1 had
different effects and functions in breast and melanoma
tumor cells. Furthermore, we confirmed, using histochemical staining of SA-β-Gal expression on sections from embedded tumor tissues, that a high amount of senescent
tumor cells were observed in tumor tissues obtained from
the E0771-SALL1 group, but not from the control groups
of E0771 tumor alone, E0771 cells transfected with
mSALL1 or vector (Fig. 7d). These results clearly suggest
that SALL1 expression in breast tumor cells directly controls tumor growth and tumorigenesis.
We next investigated whether over-expression of the
SALL1 inhibited breast tumor metastasis. In vitro wound
closure assays were utilized to determine the capacity of
tumor cell migration after transfection with or without
SALL1. We observed that over-expression of SALL1 in
E0771 and MCF7 breast tumor cells markedly inhibited
the migration of tumor cells compared with the tumor
cells alone, or tumor cells transfected with mSALL1 or
vector (Fig. 8a and Additional file 1: Figure S7A). We
then investigated whether over-expression of SALL1 affected tumor metastasis using previously established
adoptive transfer tumor models with a live imaging system [45]. Mouse E0771 tumor cells infected with or
without lentivirus carrying SALL1 or control mutated
SALL1 gene were labeled with VivoTag®680 XL and
then injected intravenously into the tail vein of NSG
mice. Tumor cell distribution and metastasis in mice
were imaged at dorsal, right lateral and ventral positions with an In Vivo Spectrum Imaging System
(IVIS) at different time points post injection. As
shown in Fig. 8b and Additional file 1: Figure S7B, at
early time points (before 3 days) post tumor cell
adoptive transfer, tumor cells randomly migrated into
different organs, including spleen, liver and lung with
similar signal densities among different groups. The
signal density of tumor cells significantly increased
and accumulated in these sites in the late time points
(after 3 days) post tumor cell transfer among the
groups of E0771 tumor cells only, or transfected with
mSALL1 or vector. This tumor cell accumulation
with strong signal density continued to persist
throughout the whole observation period (19 days),
indicating accumulated colonization of tumor cells
into the lung and liver. However, the signal density
from the tumor cells transfected with SALL1 markedly decreased in the late time points (after 3 days)
post tumor cell injection, suggesting the lower capacity of tumor metastasis and/or colonization compared with that of the other groups. To further
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confirm the live imaging results, livers and lungs from
the four groups were harvested at day 19 post tumor
injection and macro-metastatic tumors were evaluated. As expected, we observed that transferred E0771
tumor cells alone or transfected with mutated SALL1
gene or vector control, grew significantly with metastasis/colonization in lungs and livers (Fig. 8c and d).
In contrast, transfection of SALL1 in E0771 cells dramatically decreased tumor macro-metastatic numbers
both in lung and in liver surfaces. Furthermore, we confirmed, using histological staining on sections from embedded liver and lung tissues that a high number of tumor
cells infiltrated into livers and lungs obtained from control
groups of mSALL1 and vector-transfected E0771, but not
from the SALL1-transfected tumor group (Fig. 8e and
Additional file 1: Figure S7C). Our studies clearly demonstrate that SALL1 is a tumor suppressor in breast cancer
and plays a critical role in directing tumorigenesis and
metastasis.

Discussion
SALL2 and SALL4 have been recently recognized as regulators of tumorigenesis [12–15], but little information
is known about the role of the SALL1 gene in regulation
of tumor biology. In the current study, we showed that
SALL1 expression was significantly down-regulated in
specific human breast cancer subtypes based on analyses
of clinical tumor samples and cell lines. We further
demonstrated that SALL1 expression in human and
murine breast cancer cells controlled tumor cell growth
and proliferation in vitro, and that overexpression of
SALL1 inhibited tumorigenesis and metastasis in vivo in
breast cancer xenograft models. Importantly, the tumor
suppressor function mediated by SALL1 is mechanistically
related to cell senescence induction via the recruitment of
the NuRD complex in cancer cells. Our studies clearly indicate that SALL1 functions as a tumor suppressor in
breast cancer, which could be a novel target for human
breast cancer therapy.
A recent paper demonstrated that SALL1 could be a
tumor suppressor in human breast cancer, using an in vivo
RNAi screen strategy [20]. They further showed that high
expression of SALL1 was associated with significantly increased relapse-free survival, overall survival, metastasisfree survival, and tumor-free survival of breast cancer patients. However, whether and how SALL1 regulates human breast cancer is still unclear. Improved
understanding of the molecular events should open new
avenues for breast cancer clinical therapy. Our group has
extensively studied the molecular mechinasms responsible
for SALL1-mediated regulation in kidney development,
and demonstrated that endogenous SALL1 recruits and
binds to the NuRD complex to regulate transcriptional
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Fig. 7 SALL1 over-expression in breast cancer cells inhibited tumor growth and development in vivo. a Over-expression of SALL1 in E0771 breast
cancer cells dramatically inhibited tumor growth in NSG immunodeficient mice. However, SALL1 over-expression in B16F0 melanoma cells did
not affect tumor development. E0771 (2 × 105/mouse) and B16F0 (1 × 105/mouse) tumor cells infected with lentivirus carrying SALL1, mSALL1 or
vector, were subcutaneously injected into NSG mice. Tumor volumes were measured and presented as mean ± SD (n = 5 mice per group). P
values were determined by the one-way analysis of variance (ANOVA). Similar results were obtained in three repeated experiments. b Representative image
of the xenograft tumors obtained from the indicated groups at the endpoint of the experiments (day 21). c E0771 breast cancer cells over-expressed SALL1
had much lower tumor weight compared with that of other groups. Furthermore, SALL1 over-expression in B16F0 melanoma cells did not affect tumor
weight. Results shown are mean ± SD of the xenograft tumor weights from the indicated groups in the two models at the endpoint of the experiments
(day 21) (n = 5 mice per group). **p < 0.01, compared with the control groups transfected with mSALL1 and vector using unpaired t-test. d Large amounts
of senescent tumor cells were observed in SALL1-transfected E0771 tumor tissues in NSG mice. SA-β-Gal expression was determined in the tumor frozen
tissues from different groups at the endpoint of experiment. Left panels are photomicrographs of SA-β-Gal expression in tumor tissues from different
groups. Right panel is the mean ± SD of SA-β-Gal+ cell numbers per high microscope field (× 400) in the tumor tissues from 5 mice of each group. **p <
0.01, compared with the control mice of mSALL1 and vector groups using unpaired t-test

repression and specific developmental processes, such as
progenitor cell fate [4, 6, 21–23]. In this study, using both
the loss-of-function (either deletion of the conserved
NuRD-binding 12-amino acid peptide motif or substitution of the serine with a glutamic acid SALL1), and gainof-function (mutating the serine to an alanine) strategies
in vitro and in vivo studies, we clearly demonstrated that
SALL1 also utilizes a similar mechanism as in the developing kidney to recruit the NuRD complex, resulting in
the inhibition of tumorigenesis and metastasis in breast
cancer [21, 22]. In support of our novel finding, studies

from other groups have already shown that the key components of NuRD complex, including MTA1, MTA3, and
Mi-2 (CHD4), and other NuRD interacting proteins such
as LSD1, directly control the invasive growth, epithelialto-mesenchymal transition, and metastasis in breast cancer [24–26]. Furthermore, two groups identified frequent
somatic mutations in the NuRD component chromodomain helicase DNA-binding protein 4 (CHD4) in an aggressive form of uterine cancer [46, 47]. Importantly, a
more recent study demonstrated that loss of CHD4 leads
to therapeutic resistance in BRCA2 mutant ovarian cancer
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Fig. 8 SALL1 over-expression in breast cancer cells inhibited tumor metastasis in vivo. a Over-expression of SALL1 in E0771 breast cancer cells significantly
inhibited the migration of tumor cells compared with the control mSALL1 and vector-transfected tumor cells in the wound closure assays. Data shown are
from three independent experiments with similar results. b Over-expression of SALL1 in E0771 breast cancer cells markedly suppressed the tumor cell
migration and metastasis in NSG mice. Lentivirus-transfected E0771 tumor cells were stained with VivoTag®680 XL and then injected tail intravenously (5 ×
104/mouse) into NSG mice. Mice were imaged with the IVIS Spectrum at different time points following the tumor cell adoptive transfer into NSG mice.
Data shown are the dorsal, ventral, and right lateral images of representative of 5 mice per group at 2 h and day 5. Color bar represents signal intensity
scales over whole body. c and d Over-expression of SALL1 in E0771 cells dramatically decreased tumor macro-metastatic/colonized numbers in lung and
liver surfaces. Representative images shown in (c) are a representative of mouse lungs and livers obtained from the indicated groups at the endpoint of
the experiments. Tumor colonized spots were counted and results shown are mean ± SD in (d) (n = 5 mice per group). **p < 0.01, compared with the
control groups transfected with mSALL1 and vector using unpaired t-test. e H & E staining on sections from embedded lung tissues showed that high
amount of tumor cells infiltrated into lungs obtained from control groups (mSALL1 and vector), but not from the SALL1 transfection group

[48]. Our current work further suggests a causative link
between SALL1 gene regulation, NuRD complex function,
and breast cancer pathogenesis. In addition to the recruitment of the NuRD complex, SALL1 may also be involved
in the regulation of other oncogenes, such as PTEN and
c-Myc [10, 49]. However, we did not observe changes of
these two oncogenes in breast cancer cells mediated by
SALL1 over-expression (Data not shown). Notably, the
MTA1, MTA2 and MTA3 components of the NuRD
complex have been shown to play an important role in the
ER and HER2 pathways regulating the epithelialmesenchymal transition (EMT) and tumor cell invasion
and metastasis, but they have distinct effects [24, 26].
Given that ER, PR and HER2 expression levels in tumor
cells are important prognostic factors for breast cancer
outcomes, we also determined whether SALL1 had different expression in breast cancer patients with different ER,
PR or HER2 expression statuses. Our results suggested
that SALL1 expression in HER2+ patients was much
higher than that in HER2− patients. In addition, SALL1+
cell numbers in ER− patients were significant lower than

those in ER+ patients. Notably, analyses of TCGA normalized log2 transformed breast cancer argilent microarray
expression data sets clearly showed a significant decrease
of SALL1 gene expression in the basal like breast cancer,
as well as in ER−, PR− and triple negative breast cancer tissues. To further identify potential mechanism responsible
for the down-regulation of SALL1 in breast cancer, we explored promoter methylation status of the SALL1 gene via
COSMIC genome browser [27]. Consistent with the previous report showing that the SALL1 promoter was methylated in breast and other epithelial cancers [19], our
analysis also demonstrated that the genes were highly
methylated in the 2 regions of the SALL1 promoter in the
breast cancer tissues. In addition, studies from other
groups have demonstrated that SALL1, which is located at
16q12.1 is a region that was shown to undergo loss of heterozygosity (LOH) in breast, prostate, ovarian cancers and
in retinoblastoma [50, 51]. We will continue our efforts to
identify the molecular interactions and regulatory mechanisms between SALL1, NuRD, and ER, PR and HER2, in
the regulation of tumorigenesis and metastasis in breast
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cancer. In addition, given the multiple functions mediated
by different subunits of the NuRD complex, identification
of the precise assembly of NuRD components recruited
by SALL1 in breast cancer cells will facilitate our understanding the functional role of SALL1 gene in tumor
biology.
Besides the recruitment of NuRD complex, our
current study also identified senescence induction as a
novel mechanism mediated by SALL1 for the regulation
of tumor biology and tumorigenesis in breast cancer.
Cellular senescence was initially described more than
50 years ago in human fibroblasts with limited passages
in cell culture. It is now well known that senescent cells
have permanent cell cycle arrest, but remain viable,
metabolically active and possess unique transcriptional
profiles and gene regulation signatures. There are two
major categories of cellular senescence: (1) Replicative
senescence (telomere-dependent senescence) occurs due
to telomere shortening or dysfunction that triggers a
classical DNA-damage response [29, 30]; and (2) Premature senescence (extrinsic senescence or telomereindependent senescence) is induced by a variety of
extrinsic forms of stress, such as oxidative stress, DNA
damage, and activation of certain oncogenes, as well as
some inflammatory cytokines and chemokines [52]. We
have recently demonstrated that human Treg cells and
tumor cells can also induce ATM-associated DNA damage in responder T cells resulting in T cell senescence
[31, 32, 34, 53]. In addition, cellular senescence is now
thought to be a tumor suppressive mechanism that
could be a harnessed as a possible cancer therapy strategy [52]. In this study, we were the first to show that
SALL1 also plays a critical role in control of genome stability, cell-cycle progression and cell fate in breast cancer. Specifically, we observed that SALL1 gene
expression in breast cancer strongly suppresses tumor
growth and proliferation, as well as induces cell cycle S
phase arrest, which is mechanistically independent of
apoptosis or cytolysis. We further discovered that
SALL1-mediated suppression of breast cancer cells is
due to the induction of tumor cell senescence as shown
by induction of SA-β-Gal [31, 32, 53]. We identified that
ATM-associated DNA damage is responsible for SALL1mediated breast cancer cell senescence, by analyzing activation of ATM and its related targets, as well as using
loss-of-function approaches with a specific pharmacological ATM inhibitor and shRNA. Importantly, we also
provide evidence demonstrating that the SALL1mediated suppression of tumor growth, cell proliferation
and induction of tumor cell senescence depends on the
endogenous recruitment of NuRD complex in breast
cancer cells. The regulation of cell cycle transition and
DNA damage responses mediated by the NuRD complex
has been well recognized [24, 26, 54]. MTA1 and MTA2
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can directly regulate p53 stability and function, leading
to growth arrest inhibition and DNA damage response
regulation [55]. CHD4 is also as an important regulator
of the G1/S cell cycle transition and ATM-associated
DNA damage responses [56]. In addition, HDAC1 and
HDAC2 regulate the DNA-damage response and cellular
senescence [57]. Our previous studies have shown that
SALL1 binding with NuRD directly repressed Gbx2, suggesting that Gbx2 is a direct SALL1 target gene [21, 22].
Furthermore, mutating the NuRD binding motif in
SALL1 not only prevented binding of NuRD components, but the associated HDAC activity was also completely lost [21, 22]. Gbx2 was shown to be a marker of
chemoresistance in triple negative breast cancer [58].
However, how and whether Gbx2 and HDAC involve
SALL1-mediated tumor cell DNA damage and senescence is still unknown in the current study. Future studies will continue to focus on the identification of the
subunits of NuRD and target genes recruited by SALL1
in breast cancer cells responsible for the regulation of
DNA-damage response and senescence induction. Interestingly, one study suggested that SALL2 directly binds
to the p21 promoter promoting cell cycle arrest and
inhibiting cell growth [13]. SALL1 binds the p21 promoter and represses luciferase activity driven by this
promoter in a NuRD dependent manner (Our unpublished observations). Consistent with this finding, it has
been shown that CHD4 also binds the p21 promoter
and inhibits expression of this cell cycle gene [59].
Therefore, the ability of SALL1 to directly modulate cell
cycle regulatory molecules, such as p21, is another potential mechanism that needs to be explored.
Dissection of the unique molecular signaling responsible
for SALL1-mediated tumor suppression is another challenge. Our studies clearly showed that SALL1 expression
in breast tumor cells selectively modulated the MAPK p38
and ERK1/2, as well as mTOR signaling pathways in
tumor cells. In addition, the loss-of-function studies with
specific pharmacological inhibitors and lentivirus-based
shRNAs further indicated that SALL1-mediaed tumor
suppression and senescence induction is controlled by
both MAPK and mTOR signaling pathways. It is well recognized that MAPK signaling pathways play a major role
in regulating cell cycle re-entry, oncogenic ras-induced
senescence and G1 cell cycle arrest [35, 36]. Our recent
studies further demonstrated that MAPK ERK1/2 and p38
signaling controls the molecular process of human CD4
+
CD25hiFoxP3+ Treg-induced responder T cell senescence
[32]. In addition to MAPK signaling, mTOR kinase signaling activation is important for tumor cell proliferation and
senescence induction [37]. mTOR signaling is also involved in the oncogene-induced DNA damage responses
and cell senescence [39–41]. Our current studies further
identified important roles of these two signaling pathways
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in SALL1-mediated regulation in breast cancer cells. However, the results presented here are different from our previous observations showing that SALL1 induces Wnt
signaling in the developing kidney [4]. Interestingly, we did
not find activation of Wnt signaling in breast cancer
MCF-7 and E0771 cells induced by SALL1 overexpression. These results suggest that the molecular signaling utilized by SALL1 promoting its tumor suppressor
function is different from that in the regulation of organ
development. Further dissection of how MAPK signaling
and mTOR signaling cooperate and identification of
unique adaptor molecules controlling SALL1 biological
functions in tumor cells will be critical preludes for the application of SALL1 and tumor senescence as new targets
for tumor therapeutic interventions.

Conclusion
We identified SALL1 as a novel tumor suppressor in
breast cancer. We demonstrated that SALL1 can induce
tumor cell senescence as a novel mechanism of tumor
suppressor function. This molecular process acts
through NuRD recruitment and is controlled by the
MAPK and mTOR signaling pathways. These studies
not only reveal a novel role of SALL1 in breast cancer
biology, but also provide the mechanistic and causative
links among SALL1 regulation, cellular senescence,
NuRD, as well as MAPK and mTOR signaling pathways.
These important aspects should provide new insights
relevant for the development of novel therapeutic strategies in human breast cancer and other cancers as well.
Methods
Human samples and cell lines

Tumor samples were obtained from breast cancer patients treated at the Department of Surgery, Saint Louis
University from 2004 to 2015 who have given informed
consents for enrollment in a prospective tumor procurement protocol approved by the Saint Louis University
Institutional Review Board. Paired fresh tumor tissues
and normal breast tissues were obtained perioperatively
and snap frozen in liquid nitrogen. In addition, freshfrozen metastatic cutaneous melanoma tumor tissues
were also collected as controls for this study. Breast
tumor cell lines (human MDA-MB-231, MCF7, BC80,
31, 30, 29, 16, 12, 10, and murine 4 T1 and E0771),
Melanoma cell lines (Mel1938, Mel1586, Mel1860,
Mel1363, Mel1526 and Mel1628, and murine B16F0),
prostate cell line PC3 and DU145, colon cancer cell
line SW480 and lymphoma L428 and L504, as well as
normal breast cells and fibroblast cells, were either
obtained from the American Tissue Culture Collection (ATCC) or established by our group, and maintained in RPMI 1640 medium containing 10% fetal
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calf serum (FCS) and penicillin-streptomycin (Invitrogen, Inc. San Diego, CA).
Plasmid constructs

Full length flu-tagged SALL1 wild type and mutant constructs cloned into pcDNA3.1 were prepared as previously described [21]. Point mutants were created by
PCR-mediated site directed mutagenesis using QuikChange (Stratagene). The amplified PCR products were
cloned into lentivirus vector pCDH-CMV-EF1-GFP. The
nucleotide sequences of all constructs were verified by
DNA sequencing.
Immunohistochemical staining of SALL1 and
quantification method

The cell populations of SALL1+ cells in cancer and normal tissues (frozen sections) were determined using immunohistochemical staining with the Histostain®-Plus
3rd Gen IHC Detection Kit (Invitrogen, CA), as we described previously [31]. Immunohistochemical reactions
were performed using either mouse monoclonal or
rabbit polyclonal antibodies against SALL1 at dilution of
1:1500. Controls were performed by incubating slides
with the isotype control antibody instead of primary
antibodies, or second antibody alone. SALL1+ cells in
tissues were evaluated manually using a computerized
image system composed of a Leica ICC50 camera system
equipped on a Leica DM750 microscope (North Central
Instruments, Minneapolis, MN). Photographs were obtained from 20 randomly selected areas within the
tumor tissues of 10 cancer nest areas and 10 cancer
stroma areas at a high-power magnification (400 ×).
Both cancer nest and stroma areas were counted and
summed, and the means of positive cell numbers per
field reported.
Reverse-transcription PCR analysis

Total RNA was extracted from tumor or normal tissues
and cell lines using Trizol reagent (Invitrogen), and
cDNA was transcribed using a SuperScript II RT kit
(Invitrogen), both according to manufacturers’ instructions. mRNA expressions of each gene were determined
by reverse-transcription PCR using specific primers, and
mRNA levels in each samples were normalized to the
relative quantity of Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). All samples were run in triplicate. The primers for each gene used were as following:
SALL1: 5’ TGATGTAGCCAGCATGT 3′ and 5’ AAAGAATTCAGCGCAGCAC 3’.
SALL2: 5’ CCAAGAGTAAAGCGGATGAGA 3′ and
5’ AGTAAGCAGTGCCCAACTCG 3’.
SALL3: 5’ TGGGCCTTCGCTTACTAAAG 3′ and
ACAGCAGTGGCAGCTGAAG 3’.
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SALL4: 5’ AGCAGCCTCAGCAGCTACC 3′ and 5’
AAGAACTCGGCACAGCATTT 3’.
Cyclin A2: 5’ GGATGGTAGTTTTGAGTCACCAC 3′
and 5’ CACGAGGATAGCTCTCATACTGT 3’.
Cyclin B1: 5’ AACTTTCGCCTGAGCCTATTTT 3′
and 5’ TTGGTCTGACTGCTTGCTCTT 3’.
Cyclin D1: 5’ CAATGACCCCGCACGATTTC 3′ and
5’ CATGGAGGGCGGATTGGAA 3’.
Cyclin E1: 5’ ACCGGTATATGGCGACACAAGAA 3′
and 5’ TCACATACGCAAACTGGTGCAA 3’.
CDK2: 5’ GCATCTTTGCTGAGATGGTGACTC 3′
and 5’ AGTAACTCCTGGCCACACCA 3’.
CDK4: 5’ CATTCTGGTGACAAGTGGTGG 3′ and 5’
TCGGCTTCAGAGTTTCCACAG 3’.
CDK6: 5’ CCAGATGGCTCTAACCTCAGT 3′ and 5
‘AACTTCCACGAAAAAGAGGCTT 3′.
Cell growth and functional proliferation assay

Tumor cell lines were plated at 2 × 104/well in 24 wells
and transfected with one of the following plasmids:
pcDNA3.1-SALL1, pcDNA3.1-SALL4, and pcDNA3.1.
Cell growth was evaluated at different time points by
counting cell numbers. Proliferation assays were performed as previously described [60]. In brief, different
numbers of tumor cells (2 × 104, 5 × 104, or 1 × 105)
transfected with or without the related genes were cultured in 96-well plates in cell assay medium containing
2% FCS. After 56 h of culture, [3H]-thymidine was added
at a final concentration of 1 μCi/well, followed by an
additional 16 h of culture. The incorporation of [3H]thymidine was measured with a liquid scintillation
counter.
Cell cycle and apoptosis assays

Transfected cells were cultured for 72 h and apoptosis
was analyzed after staining with PE-labeled Annexin V
and 7-AAD (BD Biosciences, San Diego, CA). For cell
cycle analysis, transfected cells were fixed with 70% ethanol overnight, washed with PBS and incubated with propidium iodide (10 μg/ml) and RNase A (100 μg/ml).
Untransfected cells served as controls. All the stained
cells were analyzed on a FACSCalibur (BD Bioscience)
and the data were analyzed with FlowJo software (Tree
Star, Ashland, OR).
Colony formation assay

Five thousand per well of tumor cells infected with lentivirus carrying shRNA against SALL1 or control scramble
shRNA, or transfected with SALL1, were seeded in 6well plates with 0.4% agar for culture. Cell colonies were
stained with crystal violet and counted after 2–3 weeks
of culture.
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Senescence associated β-galactosidase (SA-β-gal) staining

Senescence associated β-Galactosidase (SA-β-Gal) activity in tumor cells was detected as we previously described [31, 32]. Briefly, tumor cell lines were transfected
with or without plasmids and cultured for 3 or 5 days.
Cells were washed in PBS (pH 7.2), fixed in 3% formaldehyde, and followed to incubate overnight at 37 °C with
freshly prepared SA-β-Gal staining solution (1 mg/ml Xgal, 5 mM K3Fe[CN]6, 5 mM K4Fe[CN]6, 2 mM MgCl2
in PBS at pH 6.0). The stained cells were washed with
H2O and examined with a microscope. For some experiments, SA-β-Gal+ populations were determined in the
transfected tumor cells after exposure to various inhibitors or combined transfection with shRNAs: ATM inhibitor KU55933 (20 μM, Tocris Bioscience); mTOR
inhibitor Rapmycin (5 μM, Sigma); MAPK inhibitors
U0126 (10 μM), SB203580 (10 μM) and SP600125
(10 μM), or PI3 Kinase inhibitor Wortminnin (10 μM)
(Calbiochemistry), or transfection with shRNAs against
p38, ERK and mTOR, for 3 or 5 days. The treated tumor
cells were then detected for SA-β-Gal expression.
Western-blotting analysis and protein interaction assays

Breast cancer cells transfected with or without plasmids
pcDNA3.1-SALL1 or pcDNA3.1-mSALL1, were cultured
for 0, 24 h, 48 h and 72 h. Whole cell lysates were prepared for western blotting. The antibodies used in western blotting are as follows: anti-SALL1, anti-ERK, antiphospho-ERK, anti-p38, anti-phospho-p38, anti-JNK,
anti-phospho-JNK, anti-phospho-p53 (ser15), antimTOR, anti-phospho-mTOR; anti-P70S6K, antiphospho-P70S6K; anti-4E-BP1, anti-phospho-4E-BP1,
anti-PTEN, anti-phospho-PTEN and anti-GAPDH rabbit
polyclonal antibodies (Cell Signaling Technology, Danvers, MA).
Protein interaction analysis of NuRD complex members with SALL1 (2–137) was performed as previously
described [21, 22]. In brief, MCF-7 breast tumor cells
were transfected with plasmids pEBG-SALL1, pEBGSALL1-S2A, and pEBG-SALL1-S2E, and allowed to expression GST-SALL1 fusion proteins for 48–72 h. Cells
were incubated for 1 h on ice in lysis buffer (1% Triton
X-100, 200 mM sucrose, 50 mM Tris pH 7.4, plus protease cokatail) and the cell suspension was disrupted by
sonication. GST-SALL1 fusions and associated protein
complexes were isolated by precipitation of 50 μg of
total protein with glutathione-Sepahrose beads (Amersham Biosciences) for 2 h at 4 °C. Protein pulldowns
were separated by SDS-PAGE and proteins detected by
western blot. Primary antibodies were all used at 1:1000
dilution and included: rabbit anti-SALL1, rabbit antiMta2 (Abcam, ab 8106), mouse anti-RbAp48 (GeneTex,
GTX 70237), rabbit anti-Hdac1 (Abcam, ab 19,845),
rabbit anti-Mbd3 (Abcam, ab 157,464). Secondary
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antibodies were used at 1:10,000 included: goat antirabbit (Sigma, A0545) and rabbit anti-mouse (Jackson
immune Research 315–035-048).
Flow cytometry analysis

The expression of DNA damage response markers on
tumor cells were determined by FACS analysis after
staining with anti-human specific antibodies conjugated
with either PE or FITC. These human antibodies included: anti-phosphorylated H2Ax, anti-phosphorylated
p53bp, and anti-phosphorylated ATM, which were purchased from Cell Signaling Technology or BD Biosciences. All stained cells were analyzed on a FACSCalibur
flow cytometer (BD Bioscience) and data analyzed with
FlowJo software (Tree Star).
Cell migration and wound healing assay

Breast cancer E0771 and MCF-7 tumor cells transfected
with Lenti-SALL1, Lenti-mSALL1 or vector, were plated
in 6-well plates and grown to confluence. A wound area
was generated by scraping cells with a 200 μl pipette tip
across the entire diameter of the dish and extensively
rinsed with the medium to remove all cellular debris.
Low-serum RPMI 1640 with mitomycin (2 μg/ml) was
then added to inhibit cell proliferation during the experiment and the closing of the wound was observed at different time points.
Lentivirus-shRNA generation and gene knockdown in
tumor cells

The methods for design and construction of shRNA specific for ERK1, ERK2, P38α, JNK1 and mTOR or scrambled lenti-shRNAs, and generation of recombinant
lentivirus carrying GFP and shRNA, have been described
previously [60]. shRNAs specific for ATM (TRCN000
0194861, TRCN0000039951 and TRCN0000360327),
mouse SALL1 (TRCN0000238153, TRCN0000238154
and TRCN0000238155) and human SALL1 (TRCN0
000003956, TRCN0000003957 and TRCN0000003958),
were purchased from Sigma Aldrich. For lentivirus infection, concentrated lentiviral supernatant with a multiplicity of infection (MOI) of 5–10 in a total volume of
0.5 ml culture medium was added to the tumor cells
growing in 24 well plates containing 8 μg/ml polybrene
(Sigma), and then centrifuged at 1000 x g for 1 h at room
temperature. The infected tumor cells were then transfected with or without pcDNA3.1-SALL-1, and induction
of senescence was determined.
In vivo tumorigenesis and metastasis studies

NOD-scid IL2Rγnull (NSG, 6–8 weeks) immunodeficient
mice were purchased from The Jackson Laboratory and
maintained in the institutional animal facility. All animal
studies have been approved by the Institutional Animal

Page 18 of 21

Care Committee. For tumorigenesis studies, mouse
E0771 (2 × 105/mouse) and B16F0 (1 × 105/mouse)
tumor cells infected with lentivirus carrying SALL1,
mSALL-1 or vector, were subcutaneously injected into
NSG mice. Five mice were included in each group.
Tumor size was measured with calipers every 2–3 days.
Tumor volume was calculated on the basis of twodimensional measurements. At the end of experiments,
the mice were sacrificed and tumors were isolated and
weighted. Furthermore, tumor tissues were embedded
into OCT and prepared for cryostat sections (4~ 8 μm),
and SA-β-Gal expression was assayed, as described
above.
For tumor metastasis studies, lentivirus-transfected
E0771 tumor cells were incubated with 100 μg/ml of
VivoTag®680 XL (PerkinElmer) for 30 min. Stained
tumor cells were washed and then injected intravenously
into the tail vein (5 × 104/mouse in 200 μl of buffered saline) into NSG mice. Five mice were included in each
group. Mice were imaged with an In Vivo Spectrum Imaging System (IVIS) (Caliper Life Science) at 120 min,
and 1, 3, 5, 7, 10, 14, 17 and 19 days post injection. The
appropriate filter set for VivoTag®680 XL imaging of
665 nm excitation and 688 nm emission was used. Mice
were imaged in the dorsal, right lateral and ventral positions at all the time points. Livers and lungs were harvested at 19 days post injection and stained with 15%
black India ink. Visible lung and liver surface macrometastatic appeared as white spots and were counted
using a dissecting microscope. Lungs were collected and
fixed in 10% formalin. For tissue morphology and metastasis evaluation, liver and lung tissues were embedded
into OCT and frozen sections (4~ 8 μm) were prepared
and stained with hematoxylin and eosin (H & E).
Statistical analysis

Statistical analysis was performed with GraphPad Prism5
software. Unless indicated otherwise, data are expressed
as mean ± standard deviation (SD). For public database
analysis, The Cancer Genome Atlas (TCGA) normalized
log2 transformed breast cancer Argilent microarray expression data sets and methylation database were downloaded from the cBioPortal (http://www.cbioportal.org/)
[27] and used to compare SALL1 mRNA expression
among the different breast cancer subtypes and solid
normal tissues, as well as analyze methylation difference
of SALL1 promoter in COSMIC between the primary
tumor in breast cancer and solid normal tissues. The
Mann-Whitney U test was utilized for statistical analysis
of association between SALL1 expression and breast
cancer subtypes. P valve < 0.05 was considered statistically significant. For multiple group comparison in vivo
studies, the one-way analysis of variance (ANOVA) was
used, followed by the Dunnett’s test for comparing
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experimental groups against a single control. For single
comparison between two groups, paired Student’s t test
was used. Nonparametric t-test was chosen if the sample
size was too small and did not fit a Gaussian distribution.

Additional file
Additional file 1: Figure S1. SALL1 and SALL4 expression levels in
different types of human cancers. (A) SALL1 expression in tumor cells in
breast cancer and melanoma tissues was determined using the
immunohistochemical staining. Numbers of SALL1+ tumor cells in
melanoma tissues were much higher than those in breast cancer tissues.
Expression level of each dot shown in the right panel is the average
numbers of SALL1+ cells per high field (400 x) in each tissue sample. The
median number of SALL1+ cells in each group is shown as a horizontal
line. Significance was determined by unpaired T test. (B) The COSMIC
analysis shows the mutations and the promoter methylation status of
SALL1 gene in breast cancer tissues. (C) SALL1 promoter genes are highly
methylated in the primary breast cancer tissues comparison with solid
normal tissues. The 2 specific molecular probes which span the proximal
promoter region of SALL1 gene were selected based on the information
in COSMIC. The box plots showed that the methylation β value of
particular promoter regions in the tissues. N indicated the number of
sample size. **P < 0.01 between 2 groups with the Mann-Whitney U test.
(D) and (E) Gene expression levels of SALL4 in different cancer cell lines
(in D) and in tumor tissues (in E) using Real-time PCR analyses. Tumor cell
lines include breast cancer (human MDA, MCF7, BC80, 31, 30, 29, 16, and
murine 4 T1 and E0771), melanoma (human Mel1938, Mel1586, Mel1860,
Mel1363, Mel1526 and Mel1628, and murine B16F0), prostate cancer (PC3
and DU145), colon cancer (SW480), and lymphoma (L428 and L504). Normal breast cell lines (BN6 and BN16), fibroblasts (F163, F160, F158 and
F112), 293 T cells, and normal breast tissues were included as controls.
mRNA levels in each cancer cell line and tumor tissue were normalized
to the relative quantity of GAPDH expression and then adjusted to the
express levels in 293 T cells (set as 1). Results shown in the histogram are
mean ± SD from three independent experiments. Figure S2. The inhibition of breast cancer cell proliferation and growth mediated by SALL1
expression is not due to the induction of apoptosis. (A) and (B) Transfection of SALL1 but not SALL4 significantly inhibited prostate cancer PC3
cell growth and proliferation. PC3 tumor cells transfected with or without
plasmids pcDNA3.1-SALL1, pcDNA3.1-SALL4, and pcDNA3.1, were cultured at a starting number of 2 × 104/well in 24 wells (A), or 1 × 104/well
in 96-well plates (B). Cell growth was evaluated at different time points
by counting cell number (in A), and cell proliferation was determined
using [3H]-thymidine assays (in B). Data are mean ± SD from three independent experiments with similar results. **p < 0.01 compared with the
vector control group. (C) Transfected breast cancer and melanoma cells
were cultured for additional 24 h. Apoptosis in transfected tumor cells
was analyzed after staining with PE-labeled Annexin V and 7-AAD. Data
shown are representative of three independent experiments with similar
results. Figure S3. Real-time PCR analyses of mRNA expression levels of
the cell cycle regulatory genes in breast cancer MDA-MB-231 cells after
transfection with SALL1. MDA-MB-231 tumor cells were transfected with
SALL1 for 72 h and then RT-PCR for gene expressions was performed.
The expression level of each gene was normalized to GAPDH expression and adjusted to the levels in vector-transfected tumor cells. Data
show mean ± SD from three independent experiments with similar results. Figure S4. SALL1 over-expression in breast cancer cells induces
tumor cell senescence. (A) Transfection of SALL1, but not SALL4 in
MCF-7 and E0771 breast cancer cells significantly induced the increased SA-β-Gal+ cell populations. In contrast, over-expression of
SALL1 in B16F0 cells did not induce senescent cells. Transfected
tumor cells were cultured for additional 3 days, and senescent cells
were analyzed using the SA-β-Gal activity assay. Data shown are
mean ± SD from three independent experiments with similar results.
**p < 0.01 compared with the vector group. (B) SALL1 expression in
breast cancer cells induced expression of phosphorylated active of
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ATM in the transfected cells. Transfected tumor cells were analyzed
for the expression of p-ATM expression after culture for 24 h using
the FACS analysis. Figure S5. SALL1 proteins expressed in transfected
breast cancer cells. Wild type SALL1 is shown at the top. Red represents the 12 amino acid region that mediates NuRD complex recruitment. Blue ovals are C2H2 zinc fingers. In mutant mSALL1, the 12
amino acid NuRD recruitment domain is deleted. In SALL1-S2E, the
serine at position 2 is mutated to a glutamic acid. This phosphomimetic mutation disrupts NuRD recruitment, similar to the deletion
mutant. In SALL1-S2A, the serine at position 2 is mutated to an alanine. This substitution prevents the inactivating serine phosphorylation, thereby enhancing SALL1 mediated NuRD recruitment and its
effects on gene transcription. Figure S6. Real-time PCR analyses of
mRNA expression levels of the other SALL family members in breast
cancer cells after transfection with SALL1. MCF7 and E0771 tumor
cells were transfected with SALL1 for 24 h and then RT-PCR was performed. The expression level of each gene was normalized to GAPDH
expression and adjusted to the levels in vector-transfected tumor
cells. Data show mean ± SD from three independent experiments
with similar results. Figure S7. SALL1 over-expression in breast cancer
cells inhibited tumor metastasis in vivo. (A) Over-expression of SALL1
in MCF-7 breast cancer cells significantly inhibited the migration of
tumor cells compared with the control mSALL1 and vectortransfected tumor cells in the wound closure assays. Data shown are
from three independent experiments with similar results. (B) Overexpression of SALL1 in E0771 breast cancer cells markedly suppressed
the tumor cell migration and metastasis in NSG mice. Lentivirustransfected E0771 tumor cells were stained with VivoTag®680 XL and
then injected tail intravenously (5 × 104/mouse) into NSG mice. Mice
were imaged with the IVIS Spectrum at different time points following the tumor cell adoptive transfer. Data shown are the dorsal, ventral, and right lateral images of representative of 5 mice per group at
day 3 and day 10. (C) H & E staining on sections from embedded
liver tissues showed that high amount of tumor cells infiltrated into
livers obtained from control groups (mSALL1 and vector), but not
from the SALL1 transfection group. (PDF 11758 kb)
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